BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 28616658)

  • 21. CD43 expression is an adverse prognostic factor in diffuse large B-Cell lymphoma.
    Mitrovic Z; Ilic I; Nola M; Aurer I; Sonicki Z; Basic-Kinda S; Radman I; Ajdukovic R; Labar B
    Clin Lymphoma Myeloma; 2009 Apr; 9(2):133-7. PubMed ID: 19406723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
    Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
    Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
    Li X; Xia B; Guo S; Zhan Z; Zhang L; Zhao D; Wu X; Zhang Y
    Ann Hematol; 2013 Jun; 92(6):807-15. PubMed ID: 23417758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation.
    Tsuyama N; Sakata S; Baba S; Mishima Y; Nishimura N; Ueda K; Yokoyama M; Terui Y; Hatake K; Kitagawa M; Ishizuka N; Tomita N; Takeuchi K
    Blood; 2017 Jul; 130(4):489-500. PubMed ID: 28522442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma.
    Giachelia M; Voso MT; Tisi MC; Martini M; Bozzoli V; Massini G; D'Aló F; Larocca LM; Leone G; Hohaus S
    Leuk Lymphoma; 2012 Mar; 53(3):411-6. PubMed ID: 21902578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy.
    Shin HC; Seo J; Kang BW; Moon JH; Chae YS; Lee SJ; Lee YJ; Han S; Seo SK; Kim JG; Sohn SK; Park TI
    Korean J Intern Med; 2014 Nov; 29(6):785-92. PubMed ID: 25378977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.
    Li ZM; Huang JJ; Xia Y; Zhu YJ; Zhao W; Wei WX; Jiang WQ; Lin TY; Huang HQ; Guan ZZ
    Eur J Haematol; 2012 Jun; 88(6):510-7. PubMed ID: 22413767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
    Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y
    Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Glasgow Prognostic Score as a significant predictor of diffuse large B cell lymphoma treated with R-CHOP in China.
    Li X; Zhang Y; Zhao W; Liu Z; Shen Y; Li J; Shen Z
    Ann Hematol; 2015 Jan; 94(1):57-63. PubMed ID: 25085376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor necrosis could reflect advanced disease status in patients with diffuse large B cell lymphoma treated with R-CHOP therapy.
    Song MK; Chung JS; Shin DY; Lim SN; Lee GW; Choi JC; Park WY; Oh SY
    Ann Hematol; 2017 Jan; 96(1):17-23. PubMed ID: 27677489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell Lymphoma.
    Jesionek-Kupnicka D; Bojo M; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Jabłońska J; Kalinka-Warzocha E; Kordek R; Młynarski W; Robak T; Warzocha K; Lech-Maranda E
    Arch Immunol Ther Exp (Warsz); 2016 Jun; 64(3):225-40. PubMed ID: 26667793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of BAD and AIF apoptotic pathways in diffuse large B-cell lymphoma.
    Troutaud D; Petit B; Bellanger C; Marin B; Gourin-Chaury MP; Petit D; Olivrie A; Feuillard J; Jauberteau MO; Bordessoule D
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):118-24. PubMed ID: 20371444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients.
    Culpin RE; Sieniawski M; Angus B; Menon GK; Proctor SJ; Milne P; McCabe K; Mainou-Fowler T
    Histopathology; 2013 Dec; 63(6):788-801. PubMed ID: 24117687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
    Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL
    Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long Non-Coding RNA Paternally Expressed Imprinted Gene 10 (PEG10) Elevates Diffuse Large B-Cell Lymphoma Progression by Regulating Kinesin Family Member 2A (KIF2A) via Targeting MiR-101-3p.
    Zhao J; Su L; Jiang J
    Med Sci Monit; 2020 Sep; 26():e922810. PubMed ID: 32976381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low expression of miRNA-224 predicts poor clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP.
    Ni H; Wang X; Liu H; Tian F; Song G
    Biomarkers; 2015; 20(4):253-7. PubMed ID: 26301883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP.
    Wong KK; Ch'ng ES; Loo SK; Husin A; Muruzabal MA; Møller MB; Pedersen LM; Pomposo MP; Gaafar A; Banham AH; Green TM; Lawrie CH
    Exp Mol Pathol; 2015 Dec; 99(3):537-45. PubMed ID: 26341140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy.
    Rambaldi A; Boschini C; Gritti G; Delaini F; Oldani E; Rossi A; Barbui AM; Caracciolo D; Ladetto M; Gueli A; De Crescenzo A; Passera R; Devizzi L; Patti C; Gianni AM; Tarella C
    Am J Hematol; 2013 Dec; 88(12):1062-7. PubMed ID: 23940056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
    Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
    Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma.
    Kwon J; Kim IH; Kim BH; Kim TM; Heo DS
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):91-8. PubMed ID: 25721091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.